AAV-mediated expression of Bcl-xL or XIAP fails to induce neuronal resistance against quinolinic acid-induced striatal lesioning

Neuroscience Letters

Volumn 436, Issue 3, 2008, Pages 326-330

  Kells, Adrian P ^a   Connor, Bronwen ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

AAV vectors; Anti apoptotic proteins; Bcl xL; Motor function; Neuroprotection; Quinolinic acid; Striatum; XIAP

Indexed keywords

CASPASE; LUCIFERASE; PARVOVIRUS VECTOR; PROTEIN BCL XL; QUINOLINIC ACID; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BRAIN DAMAGE; CELL LOSS; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; EXCITOTOXICITY; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SENSORIMOTOR FUNCTION; STRIATE CORTEX; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BCL-X PROTEIN; BEHAVIOR, ANIMAL; BRAIN INJURIES; CORPUS STRIATUM; DEPENDOVIRUS; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; GENETIC VECTORS; MALE; MICROSCOPY, IMMUNOELECTRON; MOTOR ACTIVITY; NEURONS; QUINOLINIC ACID; RATS; RATS, WISTAR; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 43049113543     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.03.051     Document Type: Article

References (45)

1. Alberch J., Perez-Navarro E., and Canals J.M. Neurotrophic factors in Huntington's disease. Progress in Brain Research 146 (2004) 195-229
2. Beal M.F., Ferrante R.J., Swartz K.J., and Kowall N.W. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. Journal of Neuroscience 11 (1991) 1649-1659
3. Bordelon Y.M., Chesselet M.F., Erecinska M., and Silver I.A. Effects of intrastriatal injection of quinolinic acid on electrical activity and extracellular ion concentrations in rat striatum in vivo. Neuroscience 83 (1998) 459-469
4. Bordelon Y.M., Mackenzie L., and Chesselet M.F. Morphology and compartmental location of cells exhibiting DNA damage after quinolinic acid injections into rat striatum. Journal of Comparative Neurology 412 (1999) 38-50
5. Brickell K.L., Nicholson L.F., Waldvogel H.J., and Faull R.L. Chemical and anatomical changes in the striatum and substantia nigra following quinolinic acid lesions in the striatum of the rat: a detailed time course of the cellular and GABA(A) receptor changes. Journal of Chemical Neuroanatomy 17 (1999) 75-97
6. Butterworth N.J., Williams L., Bullock J.Y., Love D.R., Faull R.L., and Dragunow M. Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum. Neuroscience 87 (1998) 49-53
7. Cepeda C., Ariano M.A., Calvert C.R., Flores-Hernandez J., Chandler S.H., Leavitt B.R., Hayden M.R., and Levine M.S. NMDA receptor function in mouse models of Huntington disease. Journal of Neuroscience Research 66 (2001) 525-539
8. Chen N., Luo T., Wellington C., Metzler M., McCutcheon K., Hayden M.R., and Raymond L.A. Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. Journal of Neurochemistry 72 (1999) 1890-1898
9. Cory S., and Adams J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nature Reviews. Cancer 2 (2002) 647-656
10. Deveraux Q.L., Leo E., Stennicke H.R., Welsh K., Salvesen G.S., and Reed J.C. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO Journal 18 (1999) 5242-5251
11. Dowd E., Monville C., Torres E.M., and Dunnett S.B. The corridor task: a simple test of lateralised response selection sensitive to unilateral dopamine deafferentation and graft-derived dopamine replacement in the striatum. Brain Research Bulletin 68 (2005) 24-30
12. Dure L.S.t., Wiess S., Standaert D.G., Rudolf G., Testa C.M., and Young A.B. DNA fragmentation and immediate early gene expression in rat striatum following quinolinic acid administration. Experimental Neurology 133 (1995) 207-214
13. Emerich D.F. Dose-dependent neurochemical and functional protection afforded by encapsulated CNTF-producing cells. Cell Transplantation 13 (2004) 839-844
14. Garrity-Moses M.E., Teng Q., Krudy C., Yang J., Federici T., and Boulis N.M. X-Linked inhibitor of apoptosis protein gene-based neuroprotection for the peripheral nervous system. Neurosurgery 59 (2006) 172-182
15. Garrity-Moses M.E., Teng Q., Liu J., Tanase D., and Boulis N.M. Neuroprotective adeno-associated virus Bcl-xL gene transfer in models of motor neuron disease. Muscle and Nerve 32 (2005) 734-744
16. Handley O.J., Naji J.J., Dunnett S.B., and Rosser A.E. Pharmaceutical, cellular and genetic therapies for Huntington's disease. Clinical Science 110 (2006) 73-88
17. Hickey M.A., and Chesselet M.F. Apoptosis in Huntington's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry 27 (2003) 255-265
18. Hughes P.E., Alexi T., Yoshida T., Schreiber S.S., and Knusel B. Excitotoxic lesion of rat brain with quinolinic acid induces expression of p53 messenger RNA and protein and p53-inducible genes Bax and Gadd-45 in brain areas showing DNA fragmentation. Neuroscience 74 (1996) 1143-1160
19. Jana N.R., Zemskov E.A., Wang G., and Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Human Molecular Genetics 10 (2001) 1049-1059
20. Kaspar B.K., Erickson D., Schaffer D., Hinh L., Gage F.H., and Peterson D.A. Targeted retrograde gene delivery for neuronal protection. Molecular Therapy 5 (2002) 50-56
21. Kells A.P., Fong D.M., Dragunow M., During M.J., Young D., and Connor B. AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Molecular Therapy 9 (2004) 682-688
22. A.P. Kells, R.A. Henry, B. Connor, AAV-BDNF mediated attenuation of quinolinic acid-induced neuropathology and motor function impairment, Gene Therapy, (2008), in press, doi:10.1038/gt.2008.23.
23. Kells A.P., Henry R.A., Hughes S.M., and Connor B. Verification of functional AAV-mediated neurotrophic and anti-apoptotic factor expression. Journal of Neuroscience Methods 161 (2007) 291-300
24. Kiechle T., Dedeoglu A., Kubilus J., Kowall N.W., Beal M.F., Friedlander R.M., Hersch S.M., and Ferrante R.J. Cytochrome C and caspase-9 expression in Huntington's disease. NeuroMolecular Medicine 1 (2002) 183-195
25. Kuwana T., Mackey M.R., Perkins G., Ellisman M.H., Latterich M., Schneiter R., Green D.R., and Newmeyer D.D. Bid Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 111 (2002) 331-342
26. Landwehrmeyer G.B., Standaert D.G., Testa C.M., Penney Jr. J.B., and Young A.B. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. Journal of Neuroscience 15 (1995) 5297-5307
27. Levine M.S., Klapstein G.J., Koppel A., Gruen E., Cepeda C., Vargas M.E., Jokel E.S., Carpenter E.M., Zanjani H., Hurst R.S., Efstratiadis A., Zeitlin S., and Chesselet M.F. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. Journal of Neuroscience Research 58 (1999) 515-532
28. Li S.H., Lam S., Cheng A.L., and Li X.J. Intranuclear huntingtin increases the expression of caspase-1 and induces apoptosis. Human Molecular Genetics 9 (2000) 2859-2867
29. Li T., Fan Y., Luo Y., Xiao B., and Lu C. In vivo delivery of a XIAP (BIR3-RING) fusion protein containing the protein transduction domain protects against neuronal death induced by seizures. Experimental Neurology 197 (2006) 301-308
30. Maciel E.N., Kaminski Schierle G.S., Hansson O., Brundin P., Castilho R.F., and Cyclosporin A. Bcl-2 do not inhibit quinolinic acid-induced striatal excitotoxicity in rodents. Experimental Neurology 183 (2003) 430-437
31. Martinou J.C., and Green D.R. Breaking the mitochondrial barrier. Nature Reviews. Molecular Cell Biology 2 (2001) 63-67
32. Qin Z.H., Wang Y., and Chase T.N. Stimulation of N-methyl-D-aspartate receptors induces apoptosis in rat brain. Brain Research 725 (1996) 166-176
33. Ramaswamy S., McBride J.L., Herzog C.D., Brandon E., Gasmi M., Bartus R.T., and Kordower J.H. Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease. Neurobiology of Disease 26 (2007) 375-384
34. Reddy P.H., Williams M., Charles V., Garrett L., Pike-Buchanan L., Whetsell Jr. W.O., Miller G., and Tagle D.A. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nature Genetics 20 (1998) 198-202
35. Richichi C., Lin E.J., Stefanin D., Colella D., Ravizza T., Grignaschi G., Veglianese P., Sperk G., During M.J., and Vezzani A. Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. Journal of Neuroscience 24 (2004) 3051-3059
36. Sawa A., Tomoda T., and Bae B.I. Mechanisms of neuronal cell death in Huntington's disease. Cytogenetic and Genome Research 100 (2003) 287-295
37. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., and Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39 (2000) 777-787
38. Simons M., Beinroth S., Gleichmann M., Liston P., Korneluk R.G., MacKenzie A.E., Bahr M., Klockgether T., Robertson G.S., Weller M., and Schulz J.B. Adenovirus-mediated gene transfer of inhibitors of apoptosis protein delays apoptosis in cerebellar granule neurons. Journal of Neurochemistry 72 (1999) 292-301
39. Sun Y., Savanenin A., Reddy P.H., and Liu Y.F. Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. Journal of Biological Chemistry 276 (2001) 24713-24718
40. Thomas L.B., Gates D.J., Richfield E.K., O'Brien T.F., Schweitzer J.B., and Steindler D.A. DNA end labeling (TUNEL) in Huntington's disease and other neuropathological conditions. Experimental Neurology 133 (1995) 265-272
41. Vis J.C., Schipper E., de Boer-van Huizen R.T., Verbeek M.M., de Waal R.M., Wesseling P., ten Donkelaar H.J., and Kremer B. Expression pattern of apoptosis-related markers in Huntington's disease. Acta Neuropathologica 109 (2005) 321-328
42. Wang G.H., Mitsui K., Kotliarova S., Yamashita A., Nagao Y., Tokuhiro S., Iwatsubo T., Kanazawa I., and Nukina N. Caspase activation during apoptotic cell death induced by expanded polyglutamine in N2a cells. Neuroreport 10 (1999) 2435-2438
43. Wong L.F., Ralph G.S., Walmsley L.E., Bienemann A.S., Parham S., Kingsman S.M., Uney J.B., and Mazarakis N.D. Lentiviral-mediated delivery of Bcl-2 or GDNF protects against excitotoxicity in the rat hippocampus. Molecular Therapy 11 (2005) 89-95
44. Xu D., Bureau Y., McIntyre D.C., Nicholson D.W., Liston P., Zhu Y., Fong W.G., Crocker S.J., Korneluk R.G., and Robertson G.S. Attenuation of ischemia-induced cellular and behavioral deficits by X chromosome-linked inhibitor of apoptosis protein overexpression in the rat hippocampus. Journal of Neuroscience 19 (1999) 5026-5033
45. Zeron M.M., Hansson O., Chen N., Wellington C.L., Leavitt B.R., Brundin P., Hayden M.R., and Raymond L.A. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33 (2002) 849-860